In silico drug discovery services and structure-based drug design
We offer our costumers a broad range of in silico drug discovery services and structure-based drug design: Schedule a consultation with our drug discovery experts! For our services related to kinase structure and kinase drug discovery please view the following pages. |
Schrödinger computational chemistry services
SARomics Biostructures uses industry standard and state-of-the-art software for in silico drug discovery, molecular modeling and other aspects of structure-based drug design. We are currently a licensee of a molecular modeling and computational chemistry software from Schrödinger.
Fragment-based drug discovery
It is becoming increasingly evident that the efficiency of the methods of fragment-based screening and fragment-based drug design (FBDD) is far more superior to “traditional” drug discovery methods. A multitude of recent publications clearly witness that fragment-based drug design is currently a proven excellent starting point in the discovery of new pharmaceutical compounds. IOTA's fragment libraries have been carefully assembled in collaboration with experts in the fragment-based screening and drug design areas.
Our screening services use the libraries provided by IOTA, which have been rigorously selected for their suitability for:
• fragment-based screening applications
• coverage of chemical space
• subsequent elaboration into drug-like molecules
IOTA founders Dr. Paul England and Dr. David Bailey have managed large teams of drug discovery within major pharmaceutical companies (Smith-Kline and Pfizer), as well as successful Californian biotech companies (Aurora and Incyte). A growing number of companies and academic centers are currently using IOTA’s libraries in their fragment-based screening and drug design efforts. For more information on IOTA's libraries please visit the companies site.
